Fluvastatin - Revision history

Alexander Berchansky at 12:39, 10 January 2024

2024-01-10T12:39:05Z

←Older revision		Revision as of 12:39, 10 January 2024
Line 1:		Line 1:
-	<~~applet~~ load="" size=~~"[450,380]" color="" frame="true" spin="on" Scene ="Fluvastatin/Fluvastatin/2" align~~="right" caption="Fluvastatin, also known as Lescol"/>	+	<StructureSection load='' size='340' side='right' caption='Fluvastatin, also known as Lescol' scene='1Fluvastatin/Fluvastatin/2'>
	===Better Known as: Lescol===		===Better Known as: Lescol===
	* Marketed By: Novartis <br />		* Marketed By: Novartis <br />
Line 11:		Line 11:
	===Mechanism of Action===		===Mechanism of Action===
	Fluvastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly <scene name='Fluvastatin/Hmg/1'>regulated enzyme</scene> responsible for the committed step in cholesterol synthesis.<ref>PMID:7784310</ref> Fluvastatin, like most of the statins, <scene name='Fluvastatin/Statin_fluva/1'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Fluvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Fluvastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>		Fluvastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly <scene name='Fluvastatin/Hmg/1'>regulated enzyme</scene> responsible for the committed step in cholesterol synthesis.<ref>PMID:7784310</ref> Fluvastatin, like most of the statins, <scene name='Fluvastatin/Statin_fluva/1'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Fluvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Fluvastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>
-		+	</StructureSection>
	===Pharmacokinetics===		===Pharmacokinetics===
	<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%">		<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%">

David Canner at 08:58, 10 December 2010

2010-12-10T08:58:36Z

←Older revision		Revision as of 08:58, 10 December 2010
Line 1:		Line 1:
-	<applet load="" size="~~480~~" color="" frame="true" spin="on" Scene ="Fluvastatin/Fluvastatin/2" align="right" caption="Fluvastatin, also known as Lescol"/>	+	<applet load="" size="[450,380]" color="" frame="true" spin="on" Scene ="Fluvastatin/Fluvastatin/2" align="right" caption="Fluvastatin, also known as Lescol"/>
	===Better Known as: Lescol===		===Better Known as: Lescol===
	* Marketed By: Novartis <br />		* Marketed By: Novartis <br />
Line 11:		Line 11:
	===Mechanism of Action===		===Mechanism of Action===
	Fluvastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly <scene name='Fluvastatin/Hmg/1'>regulated enzyme</scene> responsible for the committed step in cholesterol synthesis.<ref>PMID:7784310</ref> Fluvastatin, like most of the statins, <scene name='Fluvastatin/Statin_fluva/1'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Fluvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Fluvastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>		Fluvastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly <scene name='Fluvastatin/Hmg/1'>regulated enzyme</scene> responsible for the committed step in cholesterol synthesis.<ref>PMID:7784310</ref> Fluvastatin, like most of the statins, <scene name='Fluvastatin/Statin_fluva/1'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Fluvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Fluvastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>
		+
	===Pharmacokinetics===		===Pharmacokinetics===
-	~~{\| class~~="~~wikitable" border~~="1" ~~width~~="~~48%~~" ~~style~~="~~text-align:center~~"	+	<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%">
-	\|-	+	<tr>
-	~~! colspan~~="7" ~~align="center"\| Statin [[Pharmacokinetics]] at 10mg Dosage.<ref~~>~~PMID:11907637~~<~~/ref~~><~~ref>PMID~~:~~15198967</ref><ref>PMID~~:~~12686673</ref><ref>PMID~~:~~18176327</ref><ref>PMID~~: ~~17452418</ref~~><~~ref>PMID~~:~~12895195</ref>~~	+	<td style="width:100%; vertical-align:top;border-width:0px; border-style:inset">
-	\|-	+	<div style="height:100%; width: 100%">
-	~~! Parameter~~	+	{{:Statin Pharmacokinetics}}
-	~~! [[Atorvastatin]] (Lipitor)~~	+	</div>
-	~~! [[Fluvastatin]] (Lescol)~~	+	</td>
-	~~! [[Lovastatin]] (Mevacor)~~	+	</tr>
-	~~! [[Simvastatin]] (Zocor)~~	+	</table>
-	~~! [[Rosuvastatin]] (Crestor)~~	+
-	~~! [[Cerivastatin]] (Baycol)~~	+
-	\|-	+
-	~~! [[Pharmacokinetics#Tmax\|T<sub>max</sub>]] (hr)~~	+
-	~~! 2.5~~	+
-	~~! 1~~	+
-	~~! 3~~	+
-	~~! 1.5~~	+
-	~~! 4~~	+
-	~~! 1.5~~	+
-	\|-	+
-	~~! [[Pharmacokinetics#Cmax\|C<sub>max</sub>]] (ng/ml)~~	+
-	~~! 27-66~~	+
-	~~! 448~~	+
-	~~! 10-20~~	+
-	~~! 7.3~~	+
-	~~! 4.34~~	+
-	~~! 3.43~~	+
-	\|-	+
-	~~! [[Pharmacokinetics#Bioavailability_.28F.29\|Bioavailability]] (~~%)	+
-	~~! 12~~	+
-	~~! 19-29~~	+
-	~~! 5~~	+
-	~~! 5~~	+
-	~~! 20~~	+
-	~~! 60~~	+
-	\|-	+
-	~~! [[Pharmacokinetics#Protein_Binding\|Protein Binding]] (~~%)	+
-	~~! 80-90~~	+
-	~~! 99~~	+
-	~~! 95~~	+
-	~~! 95~~	+
-	~~! 88~~	+
-	~~! 99~~	+
-	\|-	+
-	~~! [[Pharmacokinetics#Half_Life_.28T1.2F2.29\|T<sub>1/2</sub~~>~~]] (hr)~~	+
-	~~! 15-30~~	+
-	~~! 2~~	+
-	~~! 3~~	+
-	~~! 2.7~~	+
-	~~! 19~~	+
-	~~! 2.2~~	+
-	\|-	+
-	~~! [[~~Pharmacokinetics~~#Area_Under_the_Curve_.28AUC.29\|AUC]] (ng/ml/hr)~~	+
-	~~! 104~~	+
-	~~! ~150~~	+
-	~~! 33~~	+
-	~~! 125~~	+
-	~~! 48~~	+
-	~~! 14.5~~	+
-	\|-	+
-	~~! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29\|IC<sub>50~~</~~sub~~>~~]] (nM)~~	+
-	~~! 154~~	+
-	~~! 198~~	+
-	~~! 800-4200~~	+
-	~~! 66~~	+
-	~~! 320~~	+
-	~~! 50-90~~	+
-	\|-	+
-	~~! Equivalent LDL Reduction Dosage (mg)~~	+
-	~~! 10~~	+
-	~~! --~~	+
-	~~! 80~~	+
-	~~! 20~~	+
-	~~! 5~~	+
-	~~! --~~	+
-	\|-	+
-	~~! Metabolism~~	+
-	~~! Hepatic~~ <br/>~~(CYP3A4)~~	+
-	~~! Hepatic~~ <br/>~~(CYP2C9)~~	+
-	~~! Hepatic~~ <br/>~~(CYP3A4)~~	+
-	~~! Hepatic <br/>(CYP3A4)~~	+
-	~~! Not <br/>Metabolized~~	+
-	~~! Hepatic <br />(CYP2C8)~~	+
-	\|}	+

	===References===		===References===

David Canner at 15:41, 8 December 2010

2010-12-08T15:41:50Z

←Older revision		Revision as of 15:41, 8 December 2010
Line 7:		Line 7:
	* 2000 Sales: $430 Million		* 2000 Sales: $430 Million
	* Importance: Was largely replaced by [[Lipitor]]. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />		* Importance: Was largely replaced by [[Lipitor]]. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />
-	* ~~The following is a list of Pharmacokinetic Parameters.~~ See: [[Pharmaceutical Drugs]] for more information	+	* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders

	===Mechanism of Action===		===Mechanism of Action===
Line 14:		Line 14:
	{\| class="wikitable" border="1" width="48%" style="text-align:center"		{\| class="wikitable" border="1" width="48%" style="text-align:center"
	\|-		\|-
-	! colspan="7" align="center"\| Statin [[~~Pharmaceutical_Drugs#Pharmacokinetics_Translated\|~~Pharmacokinetics]] at 10mg Dosage.<ref>PMID:11907637</ref><ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref><ref>PMID:12895195</ref>	+	! colspan="7" align="center"\| Statin [[Pharmacokinetics]] at 10mg Dosage.<ref>PMID:11907637</ref><ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref><ref>PMID:12895195</ref>
	\|-		\|-
	! Parameter		! Parameter
Line 24:		Line 24:
	! [[Cerivastatin]] (Baycol)		! [[Cerivastatin]] (Baycol)
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Tmax\|T<sub>max</sub>]] (hr)	+	! [[Pharmacokinetics#Tmax\|T<sub>max</sub>]] (hr)
	! 2.5		! 2.5
	! 1		! 1
Line 32:		Line 32:
	! 1.5		! 1.5
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Cmax\|C<sub>max</sub>]] (ng/ml)	+	! [[Pharmacokinetics#Cmax\|C<sub>max</sub>]] (ng/ml)
	! 27-66		! 27-66
	! 448		! 448
Line 40:		Line 40:
	! 3.43		! 3.43
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Bioavailability_.28F.29\|Bioavailability]] (%)	+	! [[Pharmacokinetics#Bioavailability_.28F.29\|Bioavailability]] (%)
	! 12		! 12
	! 19-29		! 19-29
Line 48:		Line 48:
	! 60		! 60
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Protein_Binding\|Protein Binding]] (%)	+	! [[Pharmacokinetics#Protein_Binding\|Protein Binding]] (%)
	! 80-90		! 80-90
	! 99		! 99
Line 56:		Line 56:
	! 99		! 99
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Half_Life_.28T1.2F2.29\|T<sub>1/2</sub>]] (hr)	+	! [[Pharmacokinetics#Half_Life_.28T1.2F2.29\|T<sub>1/2</sub>]] (hr)
	! 15-30		! 15-30
	! 2		! 2
Line 64:		Line 64:
	! 2.2		! 2.2
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Area_Under_the_Curve_.28AUC.29\|AUC]] (ng/ml/hr)	+	! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29\|AUC]] (ng/ml/hr)
	! 104		! 104
	! ~150		! ~150
Line 72:		Line 72:
	! 14.5		! 14.5
	\|-		\|-
-	! [[~~Pharmaceutical_Drugs~~#Inhibitory_Concentration_.28IC50.29\|IC<sub>50</sub>]] (nM)	+	! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29\|IC<sub>50</sub>]] (nM)
	! 154		! 154
	! 198		! 198

David Canner at 12:27, 1 December 2010

2010-12-01T12:27:21Z

←Older revision		Revision as of 12:27, 1 December 2010
Line 6:		Line 6:
	* Date of FDA Approval (Patent Expiration): 1993 (2011)<br />		* Date of FDA Approval (Patent Expiration): 1993 (2011)<br />
	* 2000 Sales: $430 Million		* 2000 Sales: $430 Million
-	* ~~Why You Should Care~~: Was largely replaced by [[Lipitor]]. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />	+	* Importance: Was largely replaced by [[Lipitor]]. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br />
	* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information		* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information
		+
	===Mechanism of Action===		===Mechanism of Action===
	Fluvastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly <scene name='Fluvastatin/Hmg/1'>regulated enzyme</scene> responsible for the committed step in cholesterol synthesis.<ref>PMID:7784310</ref> Fluvastatin, like most of the statins, <scene name='Fluvastatin/Statin_fluva/1'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Fluvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Fluvastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>		Fluvastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly <scene name='Fluvastatin/Hmg/1'>regulated enzyme</scene> responsible for the committed step in cholesterol synthesis.<ref>PMID:7784310</ref> Fluvastatin, like most of the statins, <scene name='Fluvastatin/Statin_fluva/1'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Fluvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Fluvastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>

David Canner at 18:33, 29 November 2010

2010-11-29T18:33:07Z

←Older revision		Revision as of 18:33, 29 November 2010
Line 1:		Line 1:
-	<applet load="" size="480" color="" frame="true" spin="on" Scene ="Fluvastatin/Fluvastatin/1" align="right" caption="Fluvastatin, also known as Lescol"/>	+	<applet load="" size="480" color="" frame="true" spin="on" Scene ="Fluvastatin/Fluvastatin/2" align="right" caption="Fluvastatin, also known as Lescol"/>
	===Better Known as: Lescol===		===Better Known as: Lescol===
	* Marketed By: Novartis <br />		* Marketed By: Novartis <br />
Line 9:		Line 9:
	* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information		* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information
	===Mechanism of Action===		===Mechanism of Action===
-	Fluvastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis~~. Fluvastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR~~.<ref>PMID:7784310</ref>	+	Fluvastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly <scene name='Fluvastatin/Hmg/1'>regulated enzyme</scene> responsible for the committed step in cholesterol synthesis.<ref>PMID:7784310</ref> Fluvastatin, like most of the statins, <scene name='Fluvastatin/Statin_fluva/1'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Fluvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Fluvastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>
-	Fluvastatin, like most of the statins, <scene name='Fluvastatin/Statin_fluva/1'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Fluvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Fluvastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>	+
	===Pharmacokinetics===		===Pharmacokinetics===
	{\| class="wikitable" border="1" width="48%" style="text-align:center"		{\| class="wikitable" border="1" width="48%" style="text-align:center"

David Canner at 18:29, 29 November 2010

2010-11-29T18:29:40Z

←Older revision		Revision as of 18:29, 29 November 2010
Line 10:		Line 10:
	===Mechanism of Action===		===Mechanism of Action===
	Fluvastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Fluvastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>		Fluvastatin is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a highly regulated enzyme responsible for the committed step in cholesterol synthesis. Fluvastatin outcompetes HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>
-		+	Fluvastatin, like most of the statins, <scene name='Fluvastatin/Statin_fluva/1'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Fluvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Fluvastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref>
	===Pharmacokinetics===		===Pharmacokinetics===
	{\| class="wikitable" border="1" width="48%" style="text-align:center"		{\| class="wikitable" border="1" width="48%" style="text-align:center"

David Canner at 18:25, 29 November 2010

2010-11-29T18:25:54Z

←Older revision		Revision as of 18:25, 29 November 2010
Line 14:		Line 14:
	{\| class="wikitable" border="1" width="48%" style="text-align:center"		{\| class="wikitable" border="1" width="48%" style="text-align:center"
	\|-		\|-
-	! colspan="6" align="center"\| Statin [[Pharmaceutical_Drugs#Pharmacokinetics_Translated\|Pharmacokinetics]] at 10mg Dosage.<ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref><ref>PMID: ~~11907637~~</ref>	+	! colspan="7" align="center"\| Statin [[Pharmaceutical_Drugs#Pharmacokinetics_Translated\|Pharmacokinetics]] at 10mg Dosage.<ref>PMID:11907637</ref><ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref><ref>PMID:12895195</ref>
	\|-		\|-
	! Parameter		! Parameter
Line 22:		Line 22:
	! [[Simvastatin]] (Zocor)		! [[Simvastatin]] (Zocor)
	! [[Rosuvastatin]] (Crestor)		! [[Rosuvastatin]] (Crestor)
		+	! [[Cerivastatin]] (Baycol)
	\|-		\|-
	! [[Pharmaceutical_Drugs#Tmax\|T<sub>max</sub>]] (hr)		! [[Pharmaceutical_Drugs#Tmax\|T<sub>max</sub>]] (hr)
Line 29:		Line 30:
	! 1.5		! 1.5
	! 4		! 4
		+	! 1.5
	\|-		\|-
	! [[Pharmaceutical_Drugs#Cmax\|C<sub>max</sub>]] (ng/ml)		! [[Pharmaceutical_Drugs#Cmax\|C<sub>max</sub>]] (ng/ml)
Line 35:		Line 37:
	! 10-20		! 10-20
	! 7.3		! 7.3
-	!4.34	+	! 4.34
		+	! 3.43
	\|-		\|-
	! [[Pharmaceutical_Drugs#Bioavailability_.28F.29\|Bioavailability]] (%)		! [[Pharmaceutical_Drugs#Bioavailability_.28F.29\|Bioavailability]] (%)
Line 43:		Line 46:
	! 5		! 5
	! 20		! 20
		+	! 60
	\|-		\|-
	! [[Pharmaceutical_Drugs#Protein_Binding\|Protein Binding]] (%)		! [[Pharmaceutical_Drugs#Protein_Binding\|Protein Binding]] (%)
Line 50:		Line 54:
	! 95		! 95
	! 88		! 88
		+	! 99
	\|-		\|-
	! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29\|T<sub>1/2</sub>]] (hr)		! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29\|T<sub>1/2</sub>]] (hr)
Line 57:		Line 62:
	! 2.7		! 2.7
	! 19		! 19
		+	! 2.2
	\|-		\|-
	! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29\|AUC]] (ng/ml/hr)		! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29\|AUC]] (ng/ml/hr)
Line 64:		Line 70:
	! 125		! 125
	! 48		! 48
		+	! 14.5
	\|-		\|-
	! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29\|IC<sub>50</sub>]] (nM)		! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29\|IC<sub>50</sub>]] (nM)
Line 71:		Line 78:
	! 66		! 66
	! 320		! 320
		+	! 50-90
	\|-		\|-
	! Equivalent LDL Reduction Dosage (mg)		! Equivalent LDL Reduction Dosage (mg)
Line 78:		Line 86:
	! 20		! 20
	! 5		! 5
		+	! --
	\|-		\|-
	! Metabolism		! Metabolism
Line 85:		Line 94:
	! Hepatic <br/>(CYP3A4)		! Hepatic <br/>(CYP3A4)
	! Not <br/>Metabolized		! Not <br/>Metabolized
		+	! Hepatic <br />(CYP2C8)
	\|}		\|}
		+
	===References===		===References===
	<references/>		<references/>
	__NOEDITSECTION__		__NOEDITSECTION__
	__NOTOC__		__NOTOC__

David Canner at 17:57, 29 November 2010

2010-11-29T17:57:48Z

←Older revision		Revision as of 17:57, 29 November 2010
Line 14:		Line 14:
	{\| class="wikitable" border="1" width="48%" style="text-align:center"		{\| class="wikitable" border="1" width="48%" style="text-align:center"
	\|-		\|-
-	! colspan="6" align="center"\| Statin [[Pharmaceutical_Drugs#Pharmacokinetics_Translated\|Pharmacokinetics]] <ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref><ref>PMID: 11907637</ref>	+	! colspan="6" align="center"\| Statin [[Pharmaceutical_Drugs#Pharmacokinetics_Translated\|Pharmacokinetics]] at 10mg Dosage.<ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref><ref>PMID: 11907637</ref>
	\|-		\|-
	! Parameter		! Parameter
Line 60:		Line 60:
	! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29\|AUC]] (ng/ml/hr)		! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29\|AUC]] (ng/ml/hr)
	! 104		! 104
-	! ~~549~~	+	! ~150
	! 33		! 33
	! 125		! 125
Line 74:		Line 74:
	! Equivalent LDL Reduction Dosage (mg)		! Equivalent LDL Reduction Dosage (mg)
	! 10		! 10
-	!	+	! --
	! 80		! 80
	! 20		! 20

David Canner at 17:54, 29 November 2010

2010-11-29T17:54:33Z

←Older revision		Revision as of 17:54, 29 November 2010
Line 18:		Line 18:
	! Parameter		! Parameter
	! [[Atorvastatin]] (Lipitor)		! [[Atorvastatin]] (Lipitor)
-	! Fluvastatin (Lescol)	+	! [[Fluvastatin]] (Lescol)
-	! Lovastatin (Mevacor)	+	! [[Lovastatin]] (Mevacor)
	! [[Simvastatin]] (Zocor)		! [[Simvastatin]] (Zocor)
	! [[Rosuvastatin]] (Crestor)		! [[Rosuvastatin]] (Crestor)

David Canner at 17:53, 29 November 2010

2010-11-29T17:53:00Z

←Older revision		Revision as of 17:53, 29 November 2010
Line 14:		Line 14:
	{\| class="wikitable" border="1" width="48%" style="text-align:center"		{\| class="wikitable" border="1" width="48%" style="text-align:center"
	\|-		\|-
-	! colspan="6" align="center"\| Statin [[Pharmaceutical_Drugs#Pharmacokinetics_Translated\|Pharmacokinetics]] ~~Comparison at 10mg doses~~<ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref>	+	! colspan="6" align="center"\| Statin [[Pharmaceutical_Drugs#Pharmacokinetics_Translated\|Pharmacokinetics]] <ref>PMID:15198967</ref><ref>PMID:12686673</ref><ref>PMID:18176327</ref><ref>PMID: 17452418</ref><ref>PMID: 11907637</ref>
	\|-		\|-
	! Parameter		! Parameter